<DOC>
	<DOCNO>NCT02922231</DOCNO>
	<brief_summary>Primary : To characterize safety RIXUBIS use normal clinical care South Korea . Secondary : To describe hemostatic effectiveness subject receive RIXUBIS normal clinical care South Korea .</brief_summary>
	<brief_title>Post-Marketing Surveillance ( Usage Results Study ) RIXUBIS Adult Pediatric Patients With Haemophilia B South Korea</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>1 . Participants congenital hemophilia B ( FIX level â‰¤5 % ) 2 . Participant participant 's legally authorize representative provide sign informed consent . 3 . Participant indicate treatment accord RIXUBIS Korean product leaflet . 1 . Participants know hypersensitivity presence contraindication RIXUBIS excipients include hamster protein 2 . Participants Disseminated Intravascular Coagulation ( DIC ) 3 . Participants sign fibrinolysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>